Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Biosimilar Substitution: US State Laws Require Physician Communication And, In Some Cases, Lower Prices

Executive Summary

Bills allowing pharmacies to substitute biosimilars for reference biologics have been enacted in all but six states. Interactive map notes state-by-state provisions.


Related Content

Mylan's Fulphila Approval: Lack Of US FDA AdComm May Be A Positive For Biosimilar Industry
Biosimilar Antitrust Pressure On J&J Grows As Walgreen, Kroger Sue Over Remicade Contracts
Mylan Is First To Clear US Neulasta Biosimilar Hurdle; At-Risk Launch May Not Be Risky
US FDA Biosimilar Guidance Update Will Relax Interchangeability Standards
Biosimilar Switching Studies Show No Adverse Efficacy Or Safety Effects, Researchers Say
Humira Biosimilar Interchangeability: The Race Begins
Best Of Biosimilar Agreement: FDA, Industry Tout Written Response, Pre-Submission Meeting
Biosimilars: Postmarketing Data Alone Not Enough For Interchangeability
Biosimilar Substitution: 'Devil' Is In Barriers To Switch In State Laws


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts